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Abstract
Background: Genes implicated in common complex disorders such as obesity, type 2 diabetes mellitus
(T2DM) or cardiovascular diseases are not disease specific, since clinically related disorders also share
genetic components. Cysteine protease Calpain 10 (CAPN10) has been associated with T2DM,
hypertension, hypercholesterolemia, increased body mass index (BMI) and polycystic ovary syndrome
(PCOS), a reproductive disorder of women in which isunlin resistance seems to play a pathogenic role.
The calpain 5 gene (CAPN5) encodes a protein homologue of CAPN10. CAPN5 has been previously
associated with PCOS by our group. In this new study, we have analysed the association of four CAPN5
gene variants(rs948976A>G, rs4945140G>A, rs2233546C>T and rs2233549G>A) with several
cardiovascular risk factors related to metabolic syndrome in general population.
Methods:  Anthropometric measurements, blood pressure, insulin, glucose and lipid profiles were
determined in 606 individuals randomly chosen from a cross-sectional population-based epidemiological
survey in the province of Segovia in Central Spain (Castille), recruited to investigate the prevalence of
anthropometric and physiological parameters related to obesity and other components of the metabolic
syndrome. Genotypes at the four polymorphic loci in CAPN5 gene were detected by polymerase chain
reaction (PCR).
Results: Genotype association analysis was significant for BMI (p ≤ 0.041), diastolic blood pressure (p =
0.015) and HDL-cholesterol levels (p = 0.025). Different CAPN5 haplotypes were also associated with
diastolic blood pressure (DBP) (0.0005 ≤ p ≤ 0.006) and total cholesterol levels (0.001 ≤ p ≤ 0.029). In
addition, the AACA haplotype, over-represented in obese individuals, is also more frequent in individuals
with metabolic syndrome defined by ATPIII criteria (p = 0.029).
Conclusion: As its homologue CAPN10, CAPN5 seems to influence traits related to increased risk for
cardiovascular diseases. Our results also may suggest CAPN5 as a candidate gene for metabolic syndrome.
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Background
Factors that increase the risk of cardiovascular disease
(CVD) include obesity, dyslipidemia, glucose intolerance,
type 2 diabetes mellitus (T2DM) and hypertension. When
these factors cluster in an individual is called metabolic
syndrome (MS), a complex disorder characterized by
impaired glucose metabolism, dyslipidemia, hyperten-
sion and obesity [1].
Calpains are a class of cysteine proteases that requires cal-
cium for its activation. They are implicated in a wide range
of cellular functions, including apoptosis, intracellular
signalling, proliferation and differentiation [2]. The
human calpain family currently comprises 16 members
and two subfamilies based on its functional domains [3].
The classic calpains are heterodimeric proteins that con-
tain five sets of EF-hand calcium-binding structures in
each subunit, similar to those in calmodulin. Calpain 10
(CAPN10), calpain 5 (CAPN5) and calpain 6 (CAPN6)
proteins belong to the non-EF-hand subfamily that lacks
these calcium-binding motifs; these calpains also differ
from the remaining members of this subfamily in the
presence of a T-domain homologous to C.elegans TRA-3, a
protein implicated in the sexual determination of the her-
maphrodite worm [4,5]. In fact, calpain 5 is the human
ortologue of the TRA-3 nematode protein, a protease that
exerts its action over a transmembrane protein called TRA-
2 which binds and inhibits the male promoting FEM pro-
teins (FEM-1, FEM-2 and FEM-3) [6,7]. Interestingly, the
knockout mice of one of the three mammalian homo-
logues of the C.elegans fem-1 gene, Fem1b, display abnor-
mal glucose homeostasis, with abnormal glucose
tolerance tests and defective glucose-stimulated insulin
secretion [8]. In humans, the FEM1A gene maps to chro-
mosome 19p13.3, a region linked to polycystic ovary syn-
drome (PCOS), a common endocrine disorder of women
of reproductive age, characterized by chronic anovulation,
infertility, hyperandrogenemia and frequently, insulin
resistance resulting in an increased prevalence of obesity,
CVD and T2DM, reason why PCOS is consider a pheno-
type closely related to metabolic syndrome. Maher y cols.
[9] have recently reported a germline missense mutation
in the FEM1A gene in a PCOS woman that was absent in
198 control chromosomes; the authors propose FEM1A as
a candidate gene for PCOS.
The  CAPN5  homologue  CAPN10  was identified as a
T2DM susceptibility locus by Horikawa et al. [10] and has
been shown to be related to proinsulin processing, insulin
secretion and insulin resistance [11,12]. Ehrman et al.
[13] and our group [14] independently published associ-
ation of CAPN10  gene with PCOS. A reanalysis of
CAPN10 gene in a larger PCOS population, allowed us to
identify specific haplotypes associated with hypercholes-
terolemia in PCOS patients [15]. Furthermore, CAPN10
has been associated with hypertension and elevated body
mass index (BMI) by different groups [16,17].
In a previous work, we analyzed four CAPN5 gene variants
(rs948976, rs4945140, rs2233546 and rs2233549) in 148
PCOS women [18]. We found that specific CAPN5 haplo-
types were overrepresented in PCOS patients. In addition,
we identified several CAPN5 alleles associated with phe-
notypic differences observed between PCOS patients,
such as the presence of obesity, cardiovascular complica-
tions, and familial antecedents of obesity, hypertension
and T2DM aggregation. These findings aimed us to inves-
tigate the relation of CAPN5 gene with cardiovascular risk
factors in the general population. Silander et al. [19] have
reported strong evidence of linkage within 11q14, the
chromosomal region that contains CAPN5 gene in a large
set of Finnish affected sibling pair families with T2DM.
Here we present the first population-based association
analysis of CAPN5 gene in traits related to hypertension
and other components of metabolic syndrome. Our
results suggest that CAPN5 alleles could modulate diasto-
lic blood pressure and cholesterol levels. In addition, a
CAPN5 haplotype over-represented in obese individuals
is also associated with the cluster of cardiovascular risk
factors defined as metabolic syndrome.
Methods
Patients
This population based study included 606 non-related
Caucasian men (n = 278, 46%) and women (n = 328,
54%) recruited by a simple random sampling approach
from a cross-sectional population-based epidemiological
survey in the province of Segovia in Central Spain (Cas-
tille) aimed at investigating the prevalence of anthropo-
metric and physiological parameters related to obesity
and other components of the metabolic syndrome [20].
Clinical characteristics of study subjects are summarized
in table 1. Individuals with previous diagnosis of type 1
diabetes were excluded from the study.
All study subjects gave their written consent to participate
in the study. The study protocol was approved by the Eth-
ics Committee of the Hospital Clinico San Carlos of
Madrid.
Phenotype measurements
We have analysed the existence of association between
CAPN5 and twelve clinical parameters: body mass index
(BMI), waist circumference (WC), systolic and diastolic
blood pressures (SBP, DBP), fasting glucose, 2-hours glu-
cose, fasting insulin, insulin resistance (IR-HOMA), total
cholesterol, HDL-cholesterol, LDL-cholesterol and triglyc-
erides (TGs).BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
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SBP and DBP were measured three times in the seated
position after 10 minutes of rest to the nearest even digit
by use of a random-zero sphygmomanometer.
After an overnight fast period, 20 ml of blood were
obtained from an antecubital vein without compression.
Plasma glucose was determined in duplicate by a glucose-
oxidase method adapted to an Autoanalyzer (Hitachi 704,
Boehringer Mannheim, Germany). Total cholesterol, trig-
lycerides and high-density lipoprotein (HDL) cholesterol
were determined by enzymatic methods using commer-
cial kits (Boehringer Mannheim, Germany). Low-density
lipoprotein (LDL) cholesterol was calculated by the
Friedewald formula. Serum insulin was determined by
RIA (Human Insulin Specific RIA kit, Linco Research Inc.,
St Louis MO, USA).
Oral glucose tolerance test (OGTT) using 75 g of glucose
was performed according to the WHO recommendations.
Two hours after glucose administration, blood samples
were obtained for the determination of glucose levels and
interpreted the results according to Genuth et al. [21]. The
crude prevalences of T2DM, impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT) were respec-
tively 8.7%, 13.6% and 15.0%.
Insulin resistance was estimated by the homeostasis
model assessment (HOMA-IR) method according to the
formula: Insulin (mU/l) × Glucose (mmol/l)/22.5 [22].
The metabolic syndrome status was established according
to ATPIII definition as it was recently modified: presence
of at least three components between abdominal obesity
(WC ≥ 102 cm men, 88 cm women), hypertriglyceridemia
(TGs  ≥ 150 mg/dl), hypertension (≥ 85/130 mmHg),
HDL-c (< 40 mg/dl men, < 50 mg/dl women) and fasting
glucose ≥ 100 mg/dl [23]. We have also classified subjects
according to the recently International Diabetes Federa-
tion (IDF) worldwide definition of the metabolic syn-
drome for Europid populations [24]. In this last
definition, central adiposity (defined as WC ≥ 94 cm for
men and ≥ 80 cm for women) is a prerequisite risk factor
for the diagnosis of the syndrome; two of the following
factors are also necessary: raised TG level (>150 mg/dl) or
specific treatment for this abnormality; reduced HDL-c (<
40 mg/dl males, < 50 mg/dl females) or specific treat-
ment; raised blood pressure (SBP ≥ 130 or DBP ≥ 85) or
treatment of previously diagnosed hypertension, raised
fasting plasma glucose (FPG ≥ 100 mg/dl) or previously
diagnosed T2DM. The crude prevalence of metabolic syn-
drome under ATPIII criteria is 12.6% and 19.8% under
IDF definition.
DNA extraction
DNA extraction from 5 ml of frozen peripheral blood was
performed in a MagNa Pure LC Instrument (Roche Diag-
nostics), using MagNa Pure LC DNA Isolation kits (Roche
Diagnostics) according to the manufacturer's instructions.
Aliquots of DNA of 5 ng/ul were obtained to carry out
PCR reactions.
Genotyping
We have analysed two polymorphisms in intron 1
(rs948976 A>G and rs4945140 G>A) and two polymor-
phisms located in the, intron 3 of CAPN5 gene (rs223546
C>T and rs223549 G>A) (Figure 1). These last two SNPs
are located in the coding region of the OMP gene, an
intronic gene integrated in the non-coding region of
CAPN5  gene, so the aminoacids encoded by the OMP
gene are not present in the CAPN5 protein. These SNPs
were selected because they had been associated with
PCOS, an insulin resistance related phenotype, in a previ-
Table 1: Clinical characteristics of study subjects
Men (n = 278) Women (n = 328)
Mean SD Mean SD
Age (years) 54.56 12.24 55.53 11.94
BMI (kg/m2) 27.47 3.42 27.41 4.58
Waist circumference 
(cm)
95.69 9.05 85.52 11.01
SBP (mmHg) 125.84 16.22 124.70 19.32
DBP(mmHg) 78.55 8.44 77.59 9.02
Fasting glucose (mg/dl) 92.79 29.78 87.74 24.05
2 h-glucose (mg/dl) 110.36 42.60 114.38 40.67
Fasting insulin (mU/l) 13.43 7.21 13.22 10.08
HOMA 3.08 1.97 2.99 3.08
TGs (mg/dl) 115.29 74.67 83.97 42.13
Cholesterol (mg/dl) 214.46 41.02 210.96 39.12
HDL-c(mg/dl) 55.64 16.55 64.85 18.64
LDL-c (mg/dl) 135.76 35.95 129.31 33.63BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
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ous work by our group [18]. The genotyping of the
selected SNPs was performed according to described pro-
cedures [18].
Statistical analysis
To analyze differences in genotype distribution, chi-
squared association studies for metabolic syndrome,
T2DM, IFG and IGT and test for deviation from Hardy-
Weinberg equilibrium, we have used tests adapted from
Sasieni [25] at the online resource available at the Insti-
tute for Human Genetics, Munich, Germany [26] or SPSS
software (Ver. 11.0.0., LEAD Technologies, Inc).
For genotype quantitative analysis, we have performed an
analysis of variance using the GLM procedure included in
SPSS software (Ver. 11.0.0., LEAD Technologies, Inc).
Normality of the dependent variables was assessed by Kol-
mogorov-Smirnov test and, when necessary, we applied
mathematical transformations (natural logarithm or
inverse of the square root) prior to the analysis. Each anal-
ysis was adjusted for age and sex. The adjusted percentage
of the phenotypic variance explained by each genotype
was estimated by subtracting the adjusted r2 value for a
model that includes the genotype from the r2 for a model
that excludes it. The Levene's test of equality of error vari-
ances was also performed for each analysis. In addition,
all values from individuals under antihypertensive, antid-
iabetic or hypocholesterolemic medication were elimi-
nated of the QTL analysis.
Linkage disequilibrium (LD) and haplotype analysis was
performed using THESIAS software based on the SEM
algorithm [27,28]. This method allows to estimate haplo-
type frequencies and haplotype effects by comparison to a
reference (the intercept) taken here as the most frequent
one. For quantitative analysis, haplotypes effects are
Scheme of CAPN5 gene organization and LD pattern of CAPN5 with neighboring genes (region spanning 140 kb aproximately) Figure 1
Scheme of CAPN5 gene organization and LD pattern of CAPN5 with neighboring genes (region spanning 140 kb aproximately). 
Analysed polymorphism are indicated by triangles.
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expressed as increases/decreases of the phenotypic mean
with respect to the intercept's one; for qualitative analysis,
results are expressed as Odds ratio (OR). All the quantita-
tive studies were corrected by age and sex. In a first
approximation, all haplotypes identified were computed
but, in order to minimize loss of power, haplotypes with
a frequency lower than 3% were excluded from further
analysis.
We have also performed a regression-based haplotype
association test using Whap software [29,30] to confirm
results obtained with the SEM approach. This software
also allows executing a Monte-Carlo test to obtain the
empirical p values. All values were standardized before the
analysis according to software instructions.
Results
Allele frequencies and genotype distribution
Polymorphism status and allele frequencies were deter-
mined in all 606 individuals. The observed allelic fre-
quencies in our population were 0.74 for A allele in
rs948976 A>G, 0.57 for G allele in rs4945140 G>A, 0.94
for C allele in rs223546 C>T and 0.80 for G allele in
rs223549G>A. The rs223546 is the less informative one,
with only 0.06 frequency for the T allele and an observed
heterozygosity of 0.11. All genotype frequencies fit the
Hardy-Weinberg equilibrium (p ≥ 0.129). Genotype dis-
tribution and Pearson's goodness-of-fit chi-square test for
deviation from Hardy-Weinberg equilibrium are shown
in table 2.
Quantitative genotype analysis
In this analysis we have found significant differences in
BMI values associated with the two markers of the first
cluster (table 3). For the rs948976 A>G polymorphism,
wild type homozygotes have the highest BMI values
(means: AA, 27.4 ± 3.7; AG, 26.6 ± 4.1; GG, 26.8 ± 3.5 kg/
m2; p = 0.035, r2 = 1.5%), whereas the presence of the
polymorphic A allele at the rs4945140 G>A locus is asso-
ciated with increased BMI values, especially in the
homozygous state (means: GG, 26.5 ± 3.7; GA, 27.2 ± 3.8;
AA, 27.8 ± 4.2 kg/m2; p = 0.041, r2 = 2.0%). The
rs4945140 G>A marker is also associated with DBP val-
ues, being again the polymorphic A allele which confers
increased risk (means: GG, 75.3 ± 8.7; GA, 77.7 ± 7.9; AA,
77.9 ± 7.8 mmHg; p = 0.015, r2 = 2.0%). Finally, HDL-c
levels are associated with rs223549G>A genotypes; raised
HDL-c values are related to the A allele (means: GG, 58.7
± 17.2; GA, 64.0 ± 21.4; AA, 65.9 ± 18.8 mg/dl; p = 0.025,
r2 = 1.7%). We have not find any other significant associ-
ations at genotype levels.
Haplotype analysis
The four polymorphisms analysed are in two LD blocks:
rs948976 A>G and rs4945140 G>A in intron 1 (D' = -1, r2
= 0.26) and rs223546 C>T and rs223549G>A in intron 3
(D' = -1, r2 = 0.02), separated from each other by a recom-
bination hot-spot (D' between blocks = 0, r2 = 7.8 × 10-5).
With this LD pattern, nine different haplotypes are possi-
ble with frequencies ranging from 1.5% to 28.5% (table
4). The leading results of haplotype analysis are shown in
table 5; the complete study is available online [see Addi-
tional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19]. The highest global haplotypic effect was
found for DBP (χ2
5d.f = 14.96 with, p = 0.010) followed by
total cholesterol (χ2
5d.f = 11.43, p = 0.043). There is also a
trend toward being associated for BMI, but it did not reach
the statistical significance level (χ2
5d.f = 10.8, p = 0.056).
No significant global associations have been found for
any of the other traits analysed (p ≥ 0.081).
According to the global haplotypic analysis, none of the
CAPN5 haplotypes are consistently associated with BMI
values and only the AA-CA haplotype shows a suggestive
association (p = 0.086), being this result significant under
de regression-based model (empirical p-value after 5.000
permutations = 0.039). We determined the frequency of
the AA-CA haplotype in obese (BMI ≥ 30 kg/m2, 148 indi-
Table 2: Genotype distribution and test for Hardy-Weinberg disequilibrium
SNP F AlLELE 1 P H-W(1 gl) GENOTYPE DISTRIBUTION
rs948976 A>G 0.74 0.39 AA AG GG
338 (55.8%) 224 (36.9%) 44 (7.3%)
rs4945140 G>A 0.57 0.40 GG GA AA
200 (33.0%) 288 (47.5%) 118 (19.5%)
rs223546 C>T 0.94 1.0 CC CT TT
536 (88.5%) 68 (11.2%) 2 (0.3%)
rs223549 G>A 0.80 0.13 GG GA AA
391 (64.5%) 184 (30.4%) 31 (5.1%)BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
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viduals) and non-obese subjects, being this haplotype
over-represented in obese population (OR = 1.63 [1.05–
2.54], p = 0.029). The haplotype analysis of BMI values in
the two clusters independently (intron 1 from one side
and intron 3 from another) showed that only the first
cluster is informative for BMI (χ22d.f 6.07, p = 0.048)
according to the genotype analysis. We have not found
evidence of association of CAPN5 alleles with abdominal
obesity estimated by waist circumference [see Additional
file 2].
With respect to blood pressure, haplotypes AG-CA (p =
0.0005) and GG-CG (p = 0.006) are related to a signifi-
cant decrease of DBP values (-14.2% and -6.1%, respec-
tively). The, independent analysis of the two clusters
showed that the second one is not significant whereas the
global measure of association of cluster 1 is of a similar
magnitude that in the full-length analysis (χ2
5d.f = 7.84, p
= 0.019)
Haplotype GG-CA is associated with higher total (p =
0.001, +29.6%) and LDL-cholesterol (p = 0.008, +36.1%).
In contrast, haplotype GG-CG is related to a reduction in
both values (p = 0.029, -8.0% and p = 0.044, -10.3%).
None of the regions are independently associated with the
trait (global p ≥ 0.090), suggesting that both are necessary
to modulate the phenotype and explaining the absence of
association in the genotype analysis. No associations have
been found for HDL-c or TG levels in the haplotypic anal-
ysis [see Additional files 10 and 12].
We have not found evidence of CAPN5 being related to
glucose or insulin levels [see Additional files 5, 6, 7].
Although the AG-CA haplotype was significantly associ-
ated with fasting glucose and 2 h-glucose levels (p ≤
0.034), the global haplotypic effect was not significant (p
≥ 0.107). In this way, T2DM, IFG or IGT do not seem to
be related to CAPN5  alleles, although the number of
affected individuals is small (49, 77 and 74 individuals
respectively) [see Additional files 15, 16, 17].
Considering metabolic syndrome under de ATPIII defini-
tion, we have found association with the obesity related
AA-CA haplotype (p = 0.029, OR = 1.80 [1.06–3.06], n =
90), although the global haplotypic effect is not signifi-
cant (p = 0.166). For the metabolic syndrome diagnosed
following the IDF criteria, the global haplotypic effect was
significant (χ2
5d.f = 11.74, p = 0.039), but only a suggestive
protective effect for the GG-CG haplotype could be deter-
mined (OR = 0.63 [0.37–1.08], p = 0.092).
Discussion
In this population-based survey, we have isolated CAPN5
as a candidate gene for cardiovascular risk factors such as
BMI, diastolic blood pressure and cholesterol. In addi-
tion, the haplotype related to obesity (AA-CA) is more fre-
quent in individuals with metabolic syndrome (ATPIII
criteria), supporting the role of obesity as an important
underlying risk factor for cardiovascular diseases [31,32].
Two groups of haplotypes can be drawn regarding cardio-
vascular disease risk factors: protective haplotypes (GG-
CG and AG-CA) and risk haplotypes (AA-CA and GG-CA).
Table 4: Haplotypes formed at CAPN5 locus with Nt g.86, Nt g.344, Nt c.1320 and Nt c.1469 polymorphisms
BASE SEQUENCE (rs948976A>G/rs4945140G>A/rs223546C>T/rs223546G>A) POPULATION FREQUENCY
AA-CG 28.55%
AG-CG 25.2%
GG-CG 19.89%
AA-CA 12.04%
GG-CA 4.2%
AG-CA 4.05%
AA-TG 2.52%
AG-TG 1.89%
GG-TG 1.52%
Table 3: Genotype analysis at the calpain 5 locus
PHENOTYPE SNP 11 12 22 p r2
BMI (kg/m2) rs948976 27.4 ± 3.7 26.6 ± 4.1 26.8 ± 3.5 0.035 1.5%
rs4945140 26.5 ± 3.7 27.2 ± 3.8 27.8 ± 4.2 0.041 2.0%
DBP (mmHg) rs4945140 75.3 ± 8.7 77.7 ± 7.9 77.9 ± 7.8 0.015 2.0%
HDL-c (mg/dl) rs223549 58.7 ± 17.2 64.0 ± 21.4 65.9 ± 18.8 0.025 1.7%
For each genotype, means and standard deviations are shown. rs948976, allele 1:allele A; rs4945140 allele 1, allele G; rs223549 allele 1, allele G.BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
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In a previous study, we analysed these four CAPN5 gene
variants in PCOS women, an anovulatory disorder of
women in which insulin resistance plays a central role
[33]. In that work, the GG-CA haplotype, associated with
cholesterol levels in this work, was over-represented in
PCOS patients. In addition, we associated several CAPN5
haplotypes with phenotypic differences observed between
PCOS patients, such as the presence of obesity (AA-CA)
and familial antecedents of obesity (AA-CA and GG-CG),
hypertension (AA-CA and GG-CG) and hypercholestero-
lemia (GG-CA). [18]. Presence of familial antecedents of
hypertension in PCOS women is a frequent finding; the
higher frequency of this haplotype among women with
familial antecedents of hypertension suggested a hyper-
tensive phenotype associated to this allele. However, in
this work, a measure of the effect of this haplotype in a
population-based analysis has revealed a blood pressure
lowering effect of the GG-CG haplotype. It is possible that
smaller sample size in PCOS study, the effect of PCOS
phenotype or PCOS related alleles have been acting as
confounding factors. Anyway, the identification of
CAPN5 gene haplotypes affecting cardiovascular risk fac-
tors also in general population reinforce CAPN5 as a can-
didate gene for metabolic syndrome related phenotypes.
It is unlikely that the OMP gene itself be causative for the
described associations in our population, given that hap-
lotype association analysis at OMP region (intron 3) was
not significant for any of the traits analysed, being neces-
sary the CAPN5 intron 1 region to modulate the pheno-
type.
Little is known about CAPN5 function in humans. It is
expressed in almost all human tissues, including testis,
ovary, liver, heart, colon, kidney and brain [5][6]. Its
homologue CAPN10 has been related to insulin secretion
and action in both functional and genetic analyses [34].
Some authors have also pointed out a role for CAPN10 in
adipocyte biology. Paul et al. [35] described how CAPN10
facilitates GLUT4 vesicle translocation during insulin-
stimulated glucose uptake in adipocytes. Another report
by Hoffstedt et al. [36] describes association of CAPN10
gene with the lipolytic sensitivity of β3-adrenoreceptors in
subcutaneous fat cells in overweight subjects. Calpains
have been also associated with adipocyte differentiation
[37]. Regarding hypertension, calpains have been
involved in mitochondrial mechanisms of oxidative stress
that leads to vascular dysfunction which causes systemic
hypertension and compensatory cardiac stiffness and
diastolic heart failure [38].
The CAPN5 ortologhe in C.elegans, TRA-3, mediates the
proteolitic cleavage of TRA-2A, a transmembrane protein
that binds and inhibits the activity of the male-promoting
FEM proteins (FEM-1, FEM-2 and FEM-3) [7]. The prote-
olitic action of TRA-3 over TRA-2 protein; produce a solu-
ble fragment that is delivered to the nucleus where it
enhances the transcriptional activity of the zinc finger
transcription factor TRA-1 which promotes female devel-
opment. Because mechanisms of sexual differentiation are
not conserved between nematodes and human, it is possi-
ble that this pathway has more general functions than in
C.elegans. In fact, the finding of abnormal glucose home-
ostasis in the knockout mice for Fem1b gene, the identifi-
cation of a germline missense mutation in FEM1A gene in
a PCOS patient and the observation of FEM1A being
downregulated in human Rhabdomyosarcoma cell lines,
support this hypothesis [8,9,39]. In humans, CAPN5 is
localized to the cytoplasma as well as to the nucleus [40].
It is possible that, in a similar way of its ortologue TRA-3,
CAPN5 could act over nuclear proteins that affect DNA
transcription such as transcription factors or related pro-
teins. Calpains are known to cleave several transcription
factors: c-Fos, c-Jun, Oct-1, p53 or C/EBP transcription
factor family among others, are calpain substrates [41-43].
Calpains can also affect DNA transcription in an indirect
way. For example, activation of NF-kappa B requires the
proteolitic degradation of its inhibitor I kappa B by cal-
pains [44].
It is also possible that the identified associations are not
related to CAPN5 gene itself, but other upstream gene in
linkage disequilibrium with the polymorphic variants
analysed. However, HapMap shows that LD block that
includes the 5' region of CAPN5  is interrupted 29 kb
upstream CAPN5 5'UTR. This region only includes the
gene that codifies B3Gn-T6, a member of the N-acetylglu-
cosaminyl transferase protein family related to muscular
dystrophies, neoplastic disorders and altered glucose
Table 5: Effects of the main haplotypes of CAPN5 by comparison to the most frequent haplotype adjusted for age and sex
TRAIT HAPLOTYPE MEAN EFFECT [CI] (%) P χ2
5d.f PGLOBAL
BMI (kg/m2) AA-CA 0.66 [-0.10 – 1.42] (+ 5.9%) 0.089 10.75 0.056
DBP (mmHg) GG-CG -2.22 [-3.82 – -0.62] (- 6.1%) 0.006 14.96 0.010
AG-CA -5.18 [-8.08 – -2.28] (- 14.2%) 0.0005
Cholesterol (mg/dl) GG-CG -7.98 [-15.18 – -0.79] (- 8.0%) 0.029 11.43 0.043
GG-CA 29.41 [11.66 – 47.17 ] (+ 29.6%) 0.001
Haplotype effects are expressed as increases or decreases with CIs and as % over the reference haplotype mean.BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
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homeostasis, although B3Gn-T6 has never been analysed
in humans [45]. The adjacent 5' LD block comprises 193
kb and includes the PHCA gene that codifies an alkaline
phytoceramidase, an integral membrane protein related
to protein biosynthesis and lipid membrane ceramide
metabolism [46]. Beyond this region, is not probably to
detect association with our marker selection. The absence
of association in the independent cluster analysis of BMI,
cholesterol levels and diastolic blood pressure with the
markers of the second LD block that contains the OMP
gene, makes improbable that the associations described
here can be due to this intragenic gene. To elucidate this
question, further analysis is being performed.
Conclusion
Results obtained from our analysis in PCOS women and
this population-based study suggest that CAPN5 is a gene
related to metabolic syndrome and related phenotypes
such as obesity, hypertension and hypercholesterolemia,
at least in the Spanish population. These results are in
accordance with the evidence of linkage of T2DM within
the chromosomal region that contains CAPN5  gene
reported by Silander et al. [19]. However, a confirmation
of our findings in independent populations is necessary to
clearly establish the role of CAPN5  in metabolic syn-
drome.
Abbreviations
CVD: cardiovascular disease
T2DM: type 2 diabetes mellitus
MS: metabolic syndrome
CAPN10: calpain 10
CAPN5: calpain 5
PCOS: polycystic ovary syndrome
BMI: body mass index
WC: waist circumference
SBP: systolic blood pressure
DBP: diastolic blood pressure
IR: insulin resistance
HOMA: homeostasis model assessment
HDL: high density lipoprotein
LDL: low density lipoprotein
OGTT: oral glucose tolerance test
IFG: impaired fasting glucose
IGT: impaired glucose tolerance
TGs: triglycerides
LD: linkage disequilibrium
OR: odds ratio
Competing interests
The authors ME Saez, R Ramirez-Lorca and A Ruiz have
declared that conflicts of interest exist. Some of the work
described here is subject to patent filings for diagnostics
purposes (WO2005116247).
Authors' contributions
MES: has genotyped samples, analysed and interpreted
data and draft the manuscript.
RRL, FJM and AR: have contributed to conception and
design of the study and revised the manuscript.
MTML, JLGL, CZ, MJMC and MSR: have contributed to
the acquisition and interpretation of data and revised the
manuscript.
All authors read and approved the final manuscript.
Additional material
Additional File 1
BMI. Haplotype association analysis of CAPN5 gene with BMI values 
using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S1.doc]
Additional File 2
Waist circumference. Haplotype association analysis of CAPN5 gene with 
waist circumference values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S2.doc]
Additional File 3
SBP. Haplotype association analysis of CAPN5 gene with systolic blood 
pressure (SBP) values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S3.doc]BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
Page 9 of 11
(page number not for citation purposes)
Additional File 4
DBP. Haplotype association analysis of CAPN5 gene with diastolic blood 
pressure (DBP) values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S4.doc]
Additional File 5
Fasting glucose. Haplotype association analysis of CAPN5 gene with fast-
ing glucose values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S5.doc]
Additional File 6
2 h-glucose. Haplotype association analysis of CAPN5 gene with glucose 
values after 2 hours from an oral glucose overload using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S6.doc]
Additional File 7
Fasting insulin. Haplotype association analysis of CAPN5 gene with fast-
ing insulin values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S7.doc]
Additional File 8
HOMA. Haplotype association analysis of CAPN5 gene with insulin 
resistance estimated using the Homeostasis Model Assessment method 
(HOMA) using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S8.doc]
Additional File 9
Cholesterol. Haplotype association analysis of CAPN5 gene with total 
cholesterol values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S9.doc]
Additional File 10
HDL-c. Haplotype association analysis of CAPN5 gene with high-density 
lipoprotein cholesterol values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S10.doc]
Additional File 11
LDL-c. Haplotype association analysis of CAPN5 gene with low-density 
lipoprotein cholesterol values using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S11.doc]
Additional File 12
TGs. Haplotype association analysis of CAPN5 gene with triglyceride val-
ues using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S12.doc]
Additional File 13
Obesity. Haplotype association analysis of CAPN5 gene with obesity 
defined as BMI ≥ 30 using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S13.doc]
Additional File 14
Obesity with hypertension. Haplotype association analysis of CAPN5 gene 
with obesity associated with hypertension (BMI ≥ 30 and SBP/DBP ≥ 
130/85) using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S14.doc]
Additional File 15
T2DM. Haplotype association analysis of CAPN5 gene with Type 2 Dia-
betes Mellitus (T2DM) using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S15.doc]
Additional File 16
IFG. Haplotype association analysis of CAPN5 gene with Impaired Fast-
ing Glucose (IFG) using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S16.doc]
Additional File 17
IGT. Haplotype association analysis of CAPN5 gene with Impaired Glu-
cose Tolerance (IGT) using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S17.doc]
Additional File 18
SM(ATPIII). Haplotype association analysis of CAPN5 gene with Meta-
bolic Syndrome using the ATPIII definition using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S18.doc]
Additional File 19
SM(IDF). Haplotype association analysis of CAPN5 gene with Metabolic 
Syndrome using the International Diabetes Federation (IDF) definition 
using Thesias software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-8-1-S19.doc]BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
Page 10 of 11
(page number not for citation purposes)
Acknowledgements
We are deeply grateful to Dr. David Tregouet for critical review of this arti-
cle. We also thank Ana Salinas for technical support.
Neocodex have been partially funded by the Ministerio de Ciencia y Tec-
nología of Spain (FIT-010000-2003-36, FIT-010000-2003-89, FIT-
0100002003-70, PTQ2003-0783 and PTQ2003-0549).
This work has also been supported by grants FISS 03/1618 from Fondo de 
Investigaciones Sanitarias and a grant from Red de Centros RCMN (C03/
08), Madrid, Spain.
References
1. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report.  Circulation 2002,
106(25):3143-3421.
2. Goll DE, Thompson VF, Li H, Wei W, Cong J: The calpain system.
Physiological reviews 2003, 83(3):731-801.
3. Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A: The therapeutic
potential of the calpain family: new aspects.  Drug Discov Today
2006.
4. Barnes TM, Hodgkin J: The tra-3 sex determination gene of
Caenorhabditis elegans encodes a member of the calpain
regulatory protease family.  The EMBO journal 1996,
15(17):4477-4484.
5. Dear N, Matena K, Vingron M, Boehm T: A new subfamily of ver-
tebrate calpains lacking a calmodulin-like domain: implica-
tions for calpain regulation and evolution.  Genomics 1997,
45(1):175-184.
6. Waghray A, Wang DS, McKinsey D, Hayes RL, Wang KK: Molecular
cloning and characterization of rat and human calpain-5.  Bio-
chem Biophys Res Commun 2004, 324(1):46-51.
7. Kuwabara PE, Perry MD: It ain't over till it's ova: germline sex
determination in C. elegans.  Bioessays 2001, 23(7):596-604.
8. Lu D, Ventura-Holman T, Li J, McMurray RW, Subauste JS, Maher JF:
Abnormal glucose homeostasis and pancreatic islet function
in mice with inactivation of the Fem1b gene.  Molecular and cel-
lular biology 2005, 25(15):6570-6577.
9. Maher JF, Hines RS, Futterweit W, Crawford S, Lu D, Shen P, Oefner
P, Kazi M, Wilson JG, Subauste JS, et al.: FEM1A is a candidate
gene for polycystic ovary syndrome.  Gynecol Endocrinol 2005,
21(6):330-335.
10. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M,
Hinokio Y, Lindner TH, Mashima H, Schwarz PE, et al.: Genetic var-
iation in the gene encoding calpain-10 is associated with type
2 diabetes mellitus.  Nature genetics 2000, 26(2):163-175.
11. Stumvoll M, Fritsche A, Madaus A, Stefan N, Weisser M, Machicao F,
Haring H: Functional significance of the UCSNP-43 polymor-
phism in the CAPN10 gene for proinsulin processing and
insulin secretion in nondiabetic Germans.  Diabetes 2001,
50(9):2161-2163.
12. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, Mott
D, Knowler WC, Cox NJ, Horikawa Y, et al.: A calpain-10 gene
polymorphism is associated with reduced muscle mRNA lev-
els and insulin resistance.  The Journal of clinical investigation 2000,
106(7):R69-73.
13. Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y, Imperial J,
Bell GI, Cox NJ: Relationship of calpain-10 genotype to pheno-
typic features of polycystic ovary syndrome.  J Clin Endocrinol
Metab 2002, 87(4):1669-1673.
14. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Royo
JL, Real LM, Ruiz A: Comment: CAPN10 alleles are associated
with polycystic ovary syndrome.  J Clin Endocrinol Metab 2002,
87(8):3971-3976.
15. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Ruiz
R, Fayez O, Galan JJ, Herreros JA, et al.: Specific CAPN10 gene
haplotypes influence the clinical profile of polycystic ovary
patients.  J Clin Endocrinol Metab 2003, 88(11):5529-5536.
16. Hong J, Li G, Li C, Hui R, Sun S, Wang J, Ye J, Cai H: [Relationship
between calpain-10 gene polymorphism, hypertension and
plasma glucose].  Zhonghua nei ke za zhi [Chinese journal of internal
medicine] 2002, 41(6):370-373.
17. Shima Y, Nakanishi K, Odawara M, Kobayashi T, Ohta H: Associa-
tion of the SNP-19 genotype 22 in the calpain-10 gene with
elevated body mass index and hemoglobin A1c levels in Jap-
anese.  Clinica chimica acta; international journal of clinical chemistry
2003, 336(1–2):89-96.
18. Gonzalez A, Saez ME, Aragon MJ, Galan JJ, Vettori P, Molina L, Rubio
C, Real LM, Ruiz A, Ramirez-Lorca R: Specific haplotypes of the
CALPAIN-5 gene are associated with polycystic ovary syn-
drome.  Human reproduction (Oxford, England) 2006, 21(4):943-951.
19. Silander K, Scott LJ, Valle TT, Mohlke KL, Stringham HM, Wiles KR,
Duren WL, Doheny KF, Pugh EW, Chines P, et al.: A large set of
Finnish affected sibling pair families with type 2 diabetes sug-
gests susceptibility loci on chromosomes 6, 11, and 14.  Dia-
betes 2004, 53(3):821-829.
20. Martinez-Larrad MT, Fernandez-Perez C, Gonzalez-Sanchez JL, Lopez
A, Fernandez-Alvarez J, Riviriego J, Serrano-Rios M: [Prevalence of
the metabolic syndrome (ATP-III criteria). Population-
based study of rural and urban areas in the Spanish province
of Segovia].  Medicina clinica 2005, 125(13):481-486.
21. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitz-
miller J, Knowler WC, Lebovitz H, Lernmark A, et al.: Follow-up
report on the diagnosis of diabetes mellitus.  Diabetes care
2003, 26(11):3160-3167.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC: Homeostasis model assessment: insulin resistance
and beta-cell function from fasting plasma glucose and insu-
lin concentrations in man.  Diabetologia 1985, 28(7):412-419.
23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Defi-
nition of metabolic syndrome: Report of the National Heart,
Lung, and Blood Institute/American Heart Association con-
ference on scientific issues related to definition.  Circulation
2004, 109(3):433-438.
24. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new
worldwide definition.  Lancet 2005, 366(9491):1059-1062.
25. Sasieni PD: From genotypes to genes: doubling the sample
size.  Biometrics 1997, 53(4):1253-1261.
26. Institute of Human Genetics   [http://ihg.gsf.de]
27. GeneCanvas   [http://ecgene.net/genecanvas/news.php]
28. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL: A new algo-
rithm for haplotype-based association analysis: the Stochas-
tic-EM algorithm.  Annals of human genetics 2004, 68(Pt
2):165-177.
29. Purcell S, Daly MJ, Sham PC: WHAP: haplotype-based associa-
tion analysis.  Bioinformatics 2006.
30. Purcell lab   [http://pngu.mgh.harvard.edu/~purcell/]
31. Vega GL: Cardiovascular outcomes for obesity and metabolic
syndrome.  Obesity research 2002, 10(Suppl 1):27S-32S.
32. Aronne LJ: Classification of obesity and assessment of obesity-
related health risks.  Obesity research 2002, 10(Suppl
2):105S-115S.
33. Essah PA, Nestler JE: Metabolic syndrome in women with poly-
cystic ovary syndrome.   Fertil Steril 2006, 86 Suppl 1():S18-S19.
34. Turner MD, Cassell PG, Hitman GA: Calpain-10: from genome
search to function.  Diabetes/metabolism research and reviews 2005,
21(6):505-514.
35. Paul DS, Harmon AW, Winston CP, Patel YM: Calpain facilitates
GLUT4 vesicle translocation during insulin-stimulated glu-
cose uptake in adipocytes.  The Biochemical journal 2003, 376(Pt
3):625-632.
36. Hoffstedt J, Naslund E, Arner P: Calpain-10 gene polymorphism
is associated with reduced beta(3)-adrenoceptor function in
human fat cells.  J Clin Endocrinol Metab 2002, 87(7):3362-3367.
37. Patel YM, Lane MD: Role of calpain in adipocyte differentiation.
Proceedings of the National Academy of Sciences of the United States of
America 1999, 96(4):1279-1284.
38. Tyagi N, Moshal KS, Ovechkin AV, Rodriguez W, Steed M, Hender-
son B, Roberts AM, Joshua IG, Tyagi SC: Mitochondrial mecha-
nism of oxidative stress and systemic hypertension in
hyperhomocysteinemia.  Journal of cellular biochemistry 2005,
96(4):665-671.
39. Ventura-Holman T, Hahn H, Subauste JS, Maher JF: The Fem1a
gene is downregulated in Rhabdomyosarcoma.  Tumour Biol
2005, 26(6):294-299.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2007, 8:1 http://www.biomedcentral.com/1471-2350/8/1
Page 11 of 11
(page number not for citation purposes)
40. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM:
Inhibition of calpain cleavage of huntingtin reduces toxicity:
accumulation of calpain/caspase fragments in the nucleus.
The Journal of biological chemistry 2004, 279(19):20211-20220.
41. Wei W, Yang H, Cao P, Menconi M, Chamberlain C, Petkova V, Has-
selgren PO: Degradation of C/EBPbeta in cultured myotubes
is calpain-dependent.  Journal of cellular physiology 2006,
208(2):386-398.
42. Piechaczyk M: Proteolysis of p53 protein by ubiquitous cal-
pains.  Methods in molecular biology (Clifton, NJ) 2000, 144:297-307.
43. Watt F, Molloy PL: Specific cleavage of transcription factors by
the thiol protease, m-calpain.  Nucleic acids research 1993,
21(22):5092-5100.
44. Lin YC, Brown K, Siebenlist U: Activation of NF-kappa B
requires proteolysis of the inhibitor I kappa B-alpha: signal-
induced phosphorylation of I kappa B-alpha alone does not
release active NF-kappa B.  Proceedings of the National Academy of
Sciences of the United States of America 1995, 92(2):552-556.
45. Whelan SA, Hart GW: Proteomic approaches to analyze the
dynamic relationships between nucleocytoplasmic protein
glycosylation and phosphorylation.  Circulation research 2003,
93(11):1047-1058.
46. Mao C, Xu R, Szulc ZM, Bielawska A, Galadari SH, Obeid LM: Clon-
ing and characterization of a novel human alkaline cerami-
dase. A mammalian enzyme that hydrolyzes
phytoceramide.  The Journal of biological chemistry 2001,
276(28):26577-26588.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/8/1/prepub